Sun Pharmaceutical Industries, Inc.

Sun Pharmaceutical Industries, Inc., a Princeton, New Jersey-based for-profit manufacturer of pharmaceutical and radiopharmaceutical products, operates exclusively as a prime contractor supplying nuclear medicine imaging products and radiopharmaceuticals to federal healthcare agencies under non-set-aside full-and-open competitive procurements. The company does not subcontract and does not pursue set-aside categories; all 50 awards in its federal portfolio are prime contracts or indefinite-delivery vehicles issued without small business designations.

Sun Pharmaceutical's federal footprint concentrates heavily within the Veterans Administration ecosystem, which accounts for roughly 72% of combined potential value across recent awards. The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 dominates this concentration with 5 awards carrying $300.3 million in combined potential value, while the Department of Veterans Affairs National Acquisition Center contributes 2 awards worth $26.7 million. The Defense Health Agency, Sun Pharmaceutical's second-largest customer by award count, holds 9 awards valued at $9.8 million combined, anchored by a $117.4 million Federal Supply Schedule contract under the Pharmaceuticals and Drugs schedule that runs through June 2026. This GSA Schedule serves as the primary vehicle for task orders placed by both the Defense Health Agency and the Department of Veterans Affairs.

Sun Pharmaceutical's capability portfolio centers on radiopharmaceuticals, isotopes, radiotracers, syringes, and shielding equipment used in nuclear medicine diagnostic imaging. Representative work includes a $521,223.75 purchase order awarded by the Defense Health Agency on November 15, 2025, for radiopharmaceuticals supporting the Department of Radiology Nuclear Medicine operations at Fort Sam Houston through September 2030; a $967,271.92 purchase order from March 2022 for nuclear medicine imaging products used in myocardial infarction, gallbladder, and breast cancer imaging; and a $250,000 single-award BPA awarded in June 2025 by the Defense Health Agency for radiation treatment agents running through June 2030. Recent BPA calls from the Defense Health Agency for radiopharmaceuticals have ranged from $19,003 to $21,839. The company's primary NAICS classification is Pharmaceutical Preparation Manufacturing (46 awards), with secondary activity in In-Vitro Diagnostic Substance Manufacturing.

Activity has been uneven across the past five years — two awards in 2020, one in 2021, two in 2022, then a gap to four awards in 2025 and one in 2026 — with only two awards (combined potential value $986 thousand) completing within the next twenty-four months. The gap between combined potential value ($465 million) and combined dollars obligated ($8.9 million, or 2% of potential) reflects the large but unobligated ceilings on indefinite-delivery vehicles, particularly the $117.4 million Federal Supply Schedule contract that anchors the portfolio.